Epoetin Beta

  title={Epoetin Beta},
  author={Christopher J. Dunn},
  • C. Dunn
  • Published 2012
  • Medicine, Biology
  • Drugs
SynopsisEpoetin beta is a recombinant form of erythropoietin, the hormone responsible for the maintenance of erythropoiesis. The drug binds to and activates receptors on erythroid progenitor cells which then develop into mature erythrocytes.Epoetin beta increases reticulocyte counts, haemoglobin levels and haemato-crit in a dose-proportional manner. These changes are accompanied by beneficial cardiovascular effects, including decreased cardiac output, resting heart rate and left ventricular… 


Epoetin (recombinant human erythropoietin). A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in anaemia and the stimulation of erythropoiesis.
Individual titration of epoetin dosage is recommended, with increases made in small increments to achieve haematocrit and haemoglobin levels of 30 to 33% and 10 to 12 g/dl, respectively, although the optimal haem atocrit for each patient should be individually determined.
Controversies in selection of epoetin dosages. Issues and answers.
Situations where the serum erythropoietin levels are normal or elevated where epoetin has been employed include boosting of haematocrit presurgery as an adjunct to autologous blood donation, treatment of anaemic patients with myelodysplastic syndromes, and improvement of athletic performances.
Erythropoietin overview--1993.
Recombinant EPO has been available clinically since mid 1989 and leads to many organ system benefits including improved muscle metabolism, decreased left ventricular hypertrophy, enhanced immune responses to hepatitis vaccine, and improved brain electrophysiology.
Impact of epoetin beta on dialyzer clearance and heparin requirements.
Pharmacokinetics and erythropoietic response to human recombinant erythropoietin in healthy men
Epoetin was well tolerated, and no antibodies were detected, and both parameters had the highest values at the 10 IU/kg dose level, while clearance tended to decrease as a function of dose.
The treatment of renal anaemia in CAPD patients with recombinant human erythropoietin.
  • I. Macdougall, M. Davies, J. Williams
  • Medicine, Biology
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • 1990
Fifteen severely anaemic patients receiving CAPD were treated with subcutaneous recombinant human erythropoietin (Epo), and Epo is a safe effective therapy for the anaemia of CAPD subjects.
Epoetin enhances erythropoiesis in normal men undergoing repeated phlebotomies
The efficacy and safety of epoetin for enhancing the erythropoietic response of normal subjects during intensive phlebotomy are supported.
Erythropoietin 1991--an overview.
  • J. Eschbach
  • Medicine
    American journal of kidney diseases : the official journal of the National Kidney Foundation
  • 1991
Patients with the anemia of renal failure, patients with progressive renal failure or chronic transplant rejection, and dialysis patients who have had incomplete correction of their anemia have yet to benefit from treatment.
The use of recombinant human erythropoietin in end stage renal disease
It is concluded that EPO is a very effective but not inexpensive therapy for the anaemia of ESRD.
Erythropoietin response and route of administration.
Thrice weekly SC and IV EPO are comparable in terms of efficacy and safety, and route of EPO administration did not influence the incidence of thrombotic and hypertensive side effects, or increases in dialysis heparin requirement and albumin, and decreases in ferritin, alpha-1-antitrypsin and ceruloplasmin during the study period.